AN2 Therapeutics, Inc. (ANTX)
NASDAQ
Closed
Sep 18, 2026
Day's Range
4.8052 wk Range
1.00Overview - ANTX - AN2 Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
136.33M
P/E (Trailing)
‪-4.66‬
P/E (Forward)
‪-6.87‬
PEG Ratio
‪0.32‬
Price / Book
‪2.63‬
EV / EBITDA
‪-3.57‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-30.80%‬
Return on Equity
‪-50.11%‬
Ownership
Shares Outstanding
36.30M
Float
21.40M
Short % of Shares Outstanding
‪7.89%‬
Held by Insiders
‪18.12%‬
Held by Institutions
‪76.54%‬
Price stats
Beta
‪-0.99‬
50-Day Avg
‪5.35‬
200-Day Avg
‪3.45‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
2 analysts
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ANTX - AN2 Therapeutics, Inc.
Peers - ANTX - AN2 Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ANTXNASDAQAN2 Therapeutics, Inc.204.34MMarket Cap+77.08%52-week change-4.66P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ANTX - AN2 Therapeutics, Inc.
About
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s current pipeline includes programs in infectious diseases, hematologic disorders, and oncology, with research efforts…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
